Item 2.02 Results of Operations and Financial Condition.

As discussed below, IO Biotech, Inc., a Delaware corporation (the "Company"), issued a press release on January 9, 2023. In its press release, the Company disclosed a cash and cash equivalents balance of approximately $142.7 million as of December 31, 2022.

Because the Company's consolidated financial statements for the year ended December 31, 2022 have not yet been finalized or audited, the preliminary statement of the Company's cash and cash equivalents as of December 31, 2022 in this Item 2.02 is subject to change, and the Company's actual cash and cash equivalents as of December 31, 2022 may differ materially from this preliminary estimate. Accordingly, you should not place undue reliance on this preliminary estimate.

Item 7.01. Regulation FD Disclosure.

On January 9, 2023, the Company issued a press release providing business updates (the "Press Release"). The press release primarily includes updates on the Company's ongoing and planned clinical trials and disclosure regarding the Company's cash and cash equivalents as of December 31, 2022.

Beginning on January 9, 2023, the Company will participate in the 41st Annual J.P. Morgan Healthcare Conference. In connection with its participation, on January 9, 2023, the Company posted to the "Investor Relations" section of the Company's website at www.investors.iobiotech.com a corporate presentation providing an update of the Company's current business and products (the "Investor Deck").

Copies of the Press Release and Investor Deck are attached hereto as Exhibits 99.1 and 99.2 respectively and are incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.

The information contained in this Current Report on Form 8-K is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits

Exhibit
Number                                   Exhibit Description

99.1           IO Biotech, Inc., Investor Deck, released on January 9, 2023

99.2           IO Biotech, Inc., Press Release, dated as of January 9, 2023

104          Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses